Compare Hewlett Packard Enterprise Co (HPE) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hewlett Packard Enterprise Co vs Novartis AG — how do they compare? Hewlett Packard Enterprise Co trades at $71.57 (market cap $94.25B), while Novartis AG trades at $143.26 (market cap $268.57B). The key difference: Novartis AG is far larger — about 2.8× Hewlett Packard Enterprise Co's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Hewlett Packard Enterprise Co for 33 Days and Novartis AG for 82 Days on average.
| HPE | NVS | |
|---|---|---|
Market Cap | $94.25B | $268.57B |
Volume | 16,060,854 | 1,532,573 |
Sector | Technology | Health |
52-Week High | $72.12 | $168.62 |
52-Week Low | $20.01 | $121.80 |
Typical Hold Time | 33 Days | 82 Days |
Enterprise Value | $108.28B | $309.89B |
Dividend Yield | 0.8% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPE's stock is trading at $72.12, up 2.2% today and near its all-time high, driven by strong AI infrastructure demand. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $1.11 surpassing the $0.932 estimate. The company secured a $1.2 billion AI server order from Vultr and raised its networking outlook, fueling bullish technical signals and positive analyst sentiment.
The outlook remains optimistic due to AI-driven growth and raised revenue targets, but risks include high valuation multiples and volatile cash flows. With a consensus price target of $70.35, slightly below the current price, the stock faces potential near-term resistance despite strong fundamentals and institutional upgrades.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
